Home Sectors Healthcare Latest Trend: Depomed (NASDAQ: DEPO)

Latest Trend: Depomed (NASDAQ: DEPO)


Depomed is part of the drug manufacturers industry and is in the healthcare sector. The company CEO is Arthur J. Higgins. Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Previous Intraday Trading Performance:

The DEPO stock showed a previous change of 1.67% with an open at 7.16 and a close of 7.30. It reached an intraday high of 7.42 and a low of 7.09.

SeekingAlpha:  Depomed’s (DEPO) CEO Arthur Higgins on Q2 2018 Results – Earnings Call Transcript


The stock has a market cap of $466.6m with 63.9m shares outstanding, of which the float is 61.3m shares. Trading volume reached 940,193 shares compared to its average volume of 1,484,484 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Depomed shares returned -5.99% and in the past 30 trading days it returned 3.99%. Over three months, it changed 0.55%. In one year it has changed 19.09% and within that year its 52-week high was 9.48 and its 52-week low was 4.31. DEPO stock is 69.37% above its 52 Week Low.

Our calculations show a 200 day moving average of 7.15 and a 50 day moving average of 7.63. Currently DEPO stock is trading 2.09% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Depomed beats by $0.03, misses on revenue


The last annual fiscal EPS for the company was reported at -1.63 that ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.30. The TTM EPS is -0.48, which comes to a TTM PE of -15.21.

The following are the last four quarter reported earnings per share:
06-30-2018:  -0.33
03-31-2018:  0.48
12-31-2017:  -0.38
09-30-2017:  -0.25

Indicators to Watch:

Based on the latest filings, there is 4.20% of insider ownership and 86.50% of institutional ownership. Short-interest is 9,540,895, which is 14.93% of shares outstanding. The short-interest ratio or days-to-cover ratio is 6.62. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The current calculated beta is 1.40

SeekingAlpha:  Depomed beats by $0.03, misses on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is -3.64%, profit margin is -9.53%, price-to-sales is 1.20 and price-to-book is 2.40.

Company Scores:

All scores are out of six:
 4  :Valuation Score
 1  :Past Performance Score
 5  :Financial Strength Score
 1  :Future Growth Score
 2  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.